Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant

Greg Monohan1 site in 1 country35 target enrollmentSeptember 2012

ConditionsHodgkin's Lymphoma Multiple Myeloma Non-Hodgkin's Lymphoma

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Hodgkin's Lymphoma
Sponsor: Greg Monohan
Enrollment: 35
Locations: 1
Primary Endpoint: Hospital length of stay
Status: Terminated
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Nestle Impact has shown efficacy in multiple surgical trials in relation to improving hospital length of stay and infection rate. 1 dose of Nestle Impact Advanced Recovery will be taken orally three times a day beginning on the morning following stem cell transplant and will continue until the day of hospital discharge.

Registry

clinicaltrials.gov

Start Date

September 2012

End Date

October 2015

Last Updated

9 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Greg Monohan

Responsible Party

Sponsor Investigator

Principal Investigator

Greg Monohan

Principal Investigator

University of Kentucky

Eligibility Criteria

Inclusion Criteria

•Patients receiving an autologous stem cell transplant using the preparative regimens of BEAM (Carmustine, Etoposide, Cytarabine, Melphalan), Melphalan 140mg/m2, or Melphalan 200mg/m2
•Any prior diet or supplement will be allowed.
•Age \>18 years.
•Ability to understand and the willingness to sign a written informed consent document.